Loading...
Loading...
CMRX| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.3M |
| Operating Expense | 24.5M |
| Operating I/L | -24.2M |
| Other Income/Expense | 2.8M |
| Interest Income | 2.8M |
| Pretax | -21.4M |
| Income Tax Expense | -2.8M |
| Net Income/Loss | -18.5M |
Chimerix, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases. Its approved product, TEMBEXA, is a medical countermeasure for smallpox. The company's clinical stage development programs include ONC201, ONC206, ONC212, and dociparstat sodium, targeting tumors, solid tumors, and hematological malignancies. Chimerix has license agreements for the development and commercialization of its products. The company generates revenue through the sale and licensing of its medicines, including brincidofovir, glycosaminoglycan compounds, and BCV for various human indications.
